Applied Genetic Technologies (AGTC) 10-K 26 Sep 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 30, 2014	Sep. 19, 2014	Mar. 27, 2014
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'AGTC	'	'
Entity Registrant Name	'APPLIED GENETIC TECHNOLOGIES CORP	'	'
Entity Central Index Key	'0001273636	'	'
Current Fiscal Year End Date	'--06-30	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Non-accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	16,387,711	'
Entity Public Float	'	'	$63.90

Balance_Sheets

Balance Sheets (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$8,623	$8,893
Short-term investments	64,450	14,000
Grants receivable	487	143
Prepaid and other current assets	1,876	475
Total current assets	75,436	23,511
Property and equipment, net	402	341
Intangible assets, net	1,565	1,630
Other assets	4	8
Total assets	77,407	25,490
Current liabilities:	'	'
Accounts payable	949	792
Accrued expenses	1,585	360
Deferred revenue	'	212
Total current liabilities	2,534	3,460
Warrant liabilities	'	110
Total liabilities	2,534	3,570
Commitments and contingencies (See Note 7)	'	'
Convertible preferred stock	'	58,103
Stockholders' equity (deficit):	'	'
Common stock, par value $.001 per share, 150,000 and 410,000 shares authorized; 14,082 and 109 shares issued and outstanding at June 30, 2014 and 2013, respectively	14	'
Additional paid-in capital	139,193	12,243
Accumulated deficit	-64,334	-48,426
Total stockholders' equity (deficit)	74,873	-36,183
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	77,407	25,490
Series B purchase rights [Member]	'	'
Current liabilities:	'	'
Series B purchase rights	'	2,096
Convertible Preferred Stock [Member]	'	'
Current liabilities:	'	'
Convertible preferred stock	'	$58,103

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Statement Of Financial Position [Abstract]	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	410,000,000
Common stock, shares issued	14,082,000	109,000
Common stock, shares outstanding	14,082,000	109,000

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Revenue:	'	'	'
Grant revenue	$917	$439	$718
Sponsored research revenue	212	503	364
Total revenue	1,129	942	1,082
Operating expenses:	'	'	'
Research and development	8,503	3,133	2,354
General and administrative	5,182	1,403	787
Total operating expenses	13,685	4,536	3,141
Loss from operations	-12,556	-3,594	-2,059
Other income (expense):	'	'	'
Interest income	42	10	'
Interest expense	'	-191	-69
Fair value adjustments	-441	-8	204
Other	-49	'	'
Total other (expense) income, net	-3,352	-1,396	135
Net loss	-15,908	-4,990	-1,924
Net loss per share, basic and diluted	($4.46)	($45.78)	($17.65)
Weighted -average shares outstanding, basic and diluted	3,568	109	109
Series B purchase rights [Member]	'	'	'
Other income (expense):	'	'	'
Fair value adjustments	($2,904)	($1,207)	'

Statements_of_Stockholders_Equ

Statements of Stockholders' Equity (Deficit) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
In Thousands, except Share data
Beginning balance at Jun. 30, 2011	($29,390)	'	$12,122	($41,512)
Beginning balance, shares at Jun. 30, 2011	'	109,000	'	'
Share-based compensation expense	24	'	24	'
Net loss	-1,924	'	'	-1,924
Ending balance at Jun. 30, 2012	-31,290	'	12,146	-43,436
Ending balance, shares at Jun. 30, 2012	'	109,000	'	'
Beneficial conversion of notes payable to preferred stock	72	'	72	'
Issuance of common stock, net of issuance costs, shares	109,000	'	'	'
Share-based compensation expense	25	'	25	'
Net loss	-4,990	'	'	-4,990
Ending balance at Jun. 30, 2013	-36,183	'	12,243	-48,426
Beginning balance, shares at Jun. 30, 2013	'	109,000	'	'
Issuance of common stock, net of issuance costs	51,801	5	51,796	'
Issuance of common stock, net of issuance costs, shares	14,082,000	4,853,000	'	'
Reclassification of warrants to purchase stock to additional paid-in capital	551	'	551	'
Conversion of convertible preferred stock to common stock	73,787	9	73,778	'
Conversion of convertible preferred stock to common stock, shares	'	9,120,000	'	'
Share-based compensation expense	825	'	825	'
Net loss	-15,908	'	'	-15,908
Ending balance at Jun. 30, 2014	$74,873	$14	$139,193	($64,334)
Ending balance, shares at Jun. 30, 2014	'	14,082,000	'	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities	'	'	'
Net loss	($15,908)	($4,990)	($1,924)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Share-based compensation expense	825	25	24
Depreciation and amortization	334	285	262
Non-cash interest expense	'	163	23
Fair value adjustments	441	8	-204
Other	49	'	'
Changes in operating assets and liabilities:	'	'	'
Decrease (increase) in grants receivable	-343	41	294
Increase in prepaid and other current assets	-1,400	-392	-22
(Decrease) increase in accounts payable	156	674	-24
Increase (decrease) in deferred revenues	-212	212	'
Increase (decrease) in accrued expenses	1,226	-10	199
Net cash used in operating activities	-11,928	-2,777	-1,372
Cash flows from investing activities	'	'	'
Purchase of property and equipment	-158	-352	-8
Purchase of and capitalized costs related to intangible assets	-218	-179	-100
Maturity of short-term investments	29,500	50	'
Purchase of short-term investments	-79,950	-14,000	'
Net cash used in investing activities	-50,826	-14,481	-108
Cash flows from financing activities	'	'	'
Proceeds from exercise of convertible preferred stock warrants	1	'	'
Proceeds from exercise of common stock options	194	'	'
Proceeds from issuance of common stock, net of issuance costs	51,607	'	'
Proceeds from issuance of convertible notes with detachable warrants	'	'	750
Proceeds from issuance of bank term note and warrants	'	507	'
Payment of bank term notes and capital lease	-1	-857	-323
Net cash provided by financing activities	62,484	25,377	427
Net (decrease) increase in cash and cash equivalents	-270	8,119	-1,053
Cash and cash equivalents, beginning of period	8,893	774	1,827
Cash and cash equivalents, end of period	8,623	8,893	774
Supplemental disclosure of cash flow information	'	'	'
Cash paid for interest	'	39	38
Supplemental disclosure of non-cash financing activities	'	'	'
Conversion of preferred stock warrants to common stock warrants	551	'	'
Capital lease of property and equipment	'	'	7
Series B purchase rights [Member]	'	'	'
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Fair value adjustments	2,904	1,207	'
Cash flows from financing activities	'	'	'
Proceeds from issuance, net of issuance costs	10,683	25,727	'
Convertible Preferred Stock [Member]	'	'	'
Supplemental disclosure of non-cash financing activities	'	'	'
Conversion of convertible preferred stock to common stock	73,787	'	'
Series B-3 convertible preferred stock [Member]	'	'	'
Supplemental disclosure of non-cash financing activities	'	'	'
Conversion of convertible preferred stock to common stock	5,000	'	'
Series B-1 convertible preferred stock [Member]	'	'	'
Supplemental disclosure of non-cash financing activities	'	'	'
Conversion of notes payable and accrued interest to Series B-1 convertible preferred stock	'	741	'
Series B-2 convertible preferred stock [Member]	'	'	'
Supplemental disclosure of non-cash financing activities	'	'	'
Conversion of convertible preferred stock to common stock	'	$834	'

Organization_and_Operations

Organization and Operations	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Organization and Operations	'
	-1	Organization and Operations:
	Applied Genetic Technologies Corporation (the “Company” or “AGTC”) was incorporated as a Florida corporation on January 19, 1999 and reincorporated as a Delaware corporation on October 24, 2003. The Company is a clinical-stage biotechnology company primarily developing gene therapy products designed to transform the lives of patients with severe inherited orphan diseases in ophthalmology. On April 1, 2014, AGTC completed its initial public offering (“IPO”) and now trades on NASDAQ under the ticker symbol AGTC.
	The Company has devoted substantially all of its efforts to research and development, including clinical trials. The Company has not completed the development of any products. The Company has generated revenue from collaboration agreements, sponsored research payments and grants, but has not generated product revenue to date and is subject to a number of risks similar to those of other early stage companies in the biotechnology industry, including dependence on key individuals, the difficulties inherent in the development of commercially viable products, the need to obtain additional capital necessary to fund the development of its products, development by the Company or its competitors of technological innovations, risks of failure of clinical studies, protection of proprietary technology, compliance with government regulations and ability to transition to large-scale production of products. As of June 30, 2014, the Company had an accumulated deficit of $64.3 million and expects to continue to incur losses for the foreseeable future. The Company has financed its operations to date primarily through sales of common stock, private placements of its convertible preferred stock, collaborations, bank debt, convertible debt financings, grant funding and cash receipts for sponsored research. At June 30, 2014, the Company had capital resources of $73.1 million consisting of cash, cash equivalents and short-term investments and believes that these resources will be sufficient to allow it to fund its current operating plan for at least the next 24 months.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	-2	Summary of Significant Accounting Policies:
		(a)	Basis of Presentation—The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
		(b)	Segment Reporting—The Company operates in only one segment. The chief operating decision-maker and management use cash flows as the primary measure to manage the business and do not segment the business for internal reporting or decision making.
		(c)	Use of estimates —The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
		(d)	Cash and cash equivalents—The Company considers all highly liquid investments with a maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and money market accounts. Cash equivalents are carried at cost, which approximates fair value due to their short-term nature.
		(e)	Short-term investments—The Company considers all investments with a maturity of 91 to 360 days at the time of purchase to be short-term investments. Short-term investments, which include certificates of deposit maturing within 91 to 360 days of date of purchase, are carried at cost which approximates their fair value due to their short-term nature.
		(f)	Inventory—The Company expenses costs for clinical materials stored for master and working viral banks that remain at the sites in anticipation of their future use at that site. Since the Company can use each of the raw materials in only a single product, each raw material is deemed to have no future economic value independent of the development status of that single drug.
		(g)	Fair value of financial instruments—The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), establishes a hierarchy of inputs used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:
	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
	Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and observable.
	To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	Items measured at fair value on a recurring basis include short-term investments, Series B purchase rights and warrant liabilities (See Note 6).
		(h)	Property and equipment—Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which are generally three to seven years. The Company periodically enters into service contracts with independent third parties for the maintenance on some of its major laboratory equipment. The maintenance contracts are generally prepaid and the Company recognizes the expense over the terms of such contracts, usually twelve months or less.
		(i)	Intangible assets—Intangible assets include licenses and patents. The Company obtains licenses from third parties and capitalizes the costs related to exclusive licenses that have alternative future use in multiple potential programs. The Company also capitalizes costs related to filing, issuance, and prosecution of patents. The Company reviews its capitalized costs periodically to determine that costs recorded include costs for patent applications that have future value. The Company evaluates costs related to patents that it is not actively pursuing and writes off any of these costs. Amortization expense is computed using the straight-line method over the estimated useful lives of the assets, which are generally eight to twenty years. The Company amortizes in-licensed patents and patent applications from the date of the applicable license and internally developed patents and patent applications from the date of the initial application. Licenses and patents converted to research use only are expensed immediately.
		(j)	Impairment of long-lived assets—The Company reviews its long-lived assets for impairment when impairment indicators are present. If impairment indicators exist, management determines whether impairment in value has occurred by comparing the estimated undiscounted cash flows from future operations with the carrying values of the assets. Management considers several indicators in assessing impairment, including trends and prospects, as well as the effects of obsolescence, demand, competition and other economic factors. For the fiscal years ended June 30, 2014, 2013, and 2012, the Company did not identify any indicators of impairment for its long-lived assets. The Company has not yet generated positive cash flows, and such cash flows may not materialize for a significant period in the future. As a result, it is reasonably possible that future evaluations of long-lived assets may result in a conclusion that such assets have been impaired.
		(k)	Warrants to purchase convertible preferred stock—In conjunction with various financing transactions, the Company issued warrants to purchase shares of its Series A-1, Series A-1A and Series B-1 preferred stock. Prior to the consummation of the Company’s IPO, the Company’s Series A-1, Series A-1A and Series B-1 preferred stock were subject to redemption under circumstances outside of the Company’s control. Therefore, for periods prior to the consummation of the IPO, the associated shares are presented as temporary equity. Consequently, for those periods, the warrants to purchase shares of Series A-1, Series A-1A and Series B-1 preferred stock were accounted for as liabilities and adjusted to fair value at the end of each reporting period. The fair value of the warrants classified as liabilities was estimated using the Black-Scholes option pricing model. The estimates in the Black-Scholes option pricing model were based, in part, on subjective assumptions, including stock price volatility, term of the warrants, risk free interest rate, dividend yield, and fair value of the preferred stock underlying the warrants. The gain or loss associated with the change in the fair value of the preferred stock warrant liability from the prior period is recognized as a component of other (expense) income, net.
		(l)	Revenue recognition—The Company has primarily generated revenue through collaboration agreements, sponsored research arrangements with nonprofit organizations for the development and commercialization of product candidates and revenues from federal research and development grant programs. The Company recognizes revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price is fixed or determinable; and (4) collection of the amounts due are reasonably assured.
	Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current liabilities. The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses, as the Company has the risks and rewards as the principal in the research and development activities.
	The Company evaluates the terms of sponsored research agreement grants and federal grants to assess the Company’s obligations and if the Company’s obligations are satisfied by the passage of time, revenue is recognized on a straight-line basis. In situations where the performance of the Company’s obligations has been satisfied when the grant is received, revenue is recognized upon receipt of the grant. Certain grants contain refund provisions. The Company reviews those refund provisions to determine the likelihood of repayment. If the likelihood of repayment of the grant is determined to be remote, the grant is recognized as revenue. If the probability of repayment is determined to be more than remote, the Company records the grant as a deferred revenue liability, until such time that the grant requirements have been satisfied.
		(m)	Income taxes—The Company uses the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
	As required by U.S. GAAP, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company files income tax returns in the U.S. federal jurisdiction and the state of Florida. As of June 30, 2014 and 2013, the Company did not have any significant uncertain tax positions.
		(n)	Research and development—Research and development costs include costs incurred in identifying, developing and testing product candidates. Costs consist primarily of payroll expenses for research related employees, laboratory costs, animal and laboratory maintenance and supplies, rent, utilities, clinical and pre-clinical expenses, as well as payments for sponsored research, scientific and regulatory consulting fees and testing. Costs are charged to expense as incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites. When outside contracts for research products or testing require advance payments, these payments are recorded on the balance sheet as a prepaid expense and subsequently recognized as an operating expense when the service is provided or when a specific milestone outlined in the contract is reached. Advance payments related to research and development were $1.4 million and $444 thousand at June 30, 2014 and 2013, respectively, and are included in other current assets on the balance sheets.
		(o)	Share-based compensation—The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the award. That cost is recognized on a straight-line basis over the period during which the employee is required to provide service in exchange for the award. The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as stock price (prior to April 2014 IPO), expected volatility and expected term. The Company’s estimates of these assumptions are primarily based on third-party valuations historical data, peer company data and judgment regarding future trends and factors. The Company accounts for stock options issued to non-employees in accordance with the provisions of ASC Subtopic 505-50, Equity-Based Payments to Non-employees, which requires valuing the stock options and measuring such stock options to their current fair value when they vest. Refer to Note 5 for details regarding the Company’s share-based compensation plans.
		(p)	Net loss per share—Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share was the same for all periods presented.
		(q)	Comprehensive loss—Comprehensive loss consists of net loss and changes in equity during a period from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all periods presented.
		(r)	New Accounting Pronouncements—In May 2014, the FASB issued guidance that requires companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. It also requires enhanced disclosures about revenue, provides guidance for transactions that were not previously addressed comprehensively, and improves guidance for multiple-element arrangements. The guidance applies to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. The guidance is effective for public companies for annual periods beginning after December 15, 2016 as well as interim periods within those annual period using either the full retrospective approach or modified retrospective approach. Early adoption is not permitted. The Company is currently evaluating the impacts of the new guidance on its financial statements.
	In July 2013, the FASB issued amended guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. The guidance requires an unrecognized tax benefit, or a portion of an unrecognized tax benefit, to be presented as a reduction of a deferred tax asset when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists, with certain exceptions. This accounting guidance was effective for annual and interim periods beginning after December 15, 2013. The Company adopted this new guidance beginning with its interim financial statements for the three months ended March 31, 2014. The adoption of this standard did not have a material impact on the Company’s financial statements.

Property_and_Equipment_Net

Property and Equipment, Net	12 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Property and Equipment, Net	'
	-3	Property and Equipment, Net:
	Property and equipment consists of the following:
			At June 30,
	In thousands		2014			2013
	Laboratory equipment		$	1,085		$	945
	Office equipment			92			79
	Leasehold improvements			8			8
	Software			41			32
	Property and equipment, gross			1,226			1,064
	Less: Accumulated depreciation and amortization			(824	)		(723	)
	Property and equipment, net		$	402		$	341
	Depreciation and amortization expense was $101 thousand, $64 thousand and $54 thousand for the fiscal years ended June 30, 2014, 2013 and 2012, respectively. Depreciation and amortization expense of $14 thousand, $14 thousand and $10 thousand was included in general and administrative expenses for the years ended June 30, 2014, 2013 and 2012, respectively. Depreciation and amortization expense of $87 thousand, $50 thousand and $44 thousand was included in research and development expenses for each of the fiscal years ended June 30, 2014, 2013 and 2012, respectively.

Intangible_Assets_Net

Intangible Assets, Net	12 Months Ended
	Jun. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Intangible Assets, Net	'
	-4	Intangible Assets, Net:
	Intangible assets subject to amortization consist of the following:
			At June 30, 2014
	In thousands		Cost		Accumulated		Net of
					Amortization		Accumulated
							Amortization
	Licenses		$	1,143	$	751	$	392
	Patents			1,892		719		1,173
	Intangible assets, net		$	3,035	$	1,470	$	1,565
			At June 30, 2013
	In thousands		Cost		Accumulated		Net of
					Amortization		Accumulated
							Amortization
	Licenses		$	1,080	$	672	$	408
	Patents			1,791		569		1,222
	Intangible assets, net		$	2,871	$	1,241	$	1,630
	Amortization expense related to intangible assets for the years ended June 30, 2014, 2013 and 2012 was $233 thousand, $221 thousand and $208 thousand, respectively. All amortization expense related to intangible assets is included in research and development expenses on the statements of operations.
	Estimated amortization expense for the next five years and thereafter is as follows:
	Fiscal Year Ending June 30,		Amount
	2015		$	234
	2016			222
	2017			219
	2018			210
	2019			169
	Thereafter			511
			$	1,565

Sharebased_Compensation_Plans

Share-based Compensation Plans	12 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-based Compensation Plans	'
	-5	Share-based Compensation Plans:
	The Company primarily uses stock options to provide long-term incentives for its employees, non-employee directors and certain consultants. Effective upon the closing of the Company’s sale of shares of Series B-3 preferred stock on November 5, 2013, the Company’s stockholders approved an amendment to the 2011 Stock Incentive Plan to increase the total number of shares available for issue under the plan to 909,000. With the approval of the 2013 Equity and Incentive Plan as discussed below, no new awards will be granted under the Company’s 2011 Stock Incentive Plan in the future.
	Upon the effectiveness on March 26, 2014 of the Company’s registration statement on Form S-1 relating to its IPO, the Company’s stockholders approved the 2013 Equity and Incentive Plan. As of June 30, 2014, the total number of shares available for issue under the 2013 Equity and Incentive plan was 1,151,428. As of June 30, 2014, awards for 839,465 shares of common stock are available for issuance pursuant to awards under the Plan.
	The Board of Directors has the authority to select the individuals to whom options are granted and determine the terms of each option, including (i) the number of shares of common stock subject to the option; (ii) the date on which the option becomes exercisable; (iii) the option exercise price, which, in the case of incentive stock options, must be at least 100% (110% in the case of incentive stock options granted to a stockholder owning in excess of 10% of the Company’s stock) of the fair market value of the common stock as of the date of grant; and (iv) the duration of the option (which, in the case of incentive stock options, may not exceed ten years). Options typically vest over a three- or four-year period.
	A summary of the stock option activity is as follows:
			For the years ended June 30,
			2014						2013					2012
	(In thousands, except per share amounts)		Shares			Weighted			Shares			Weighted		Shares			Weighted
						Average						Average					Average
						Exercise						Exercise					Exercise
						Price						Price					Price
	Outstanding, beginning of year			380		$	1.45			133		$	3.5		133		$	3.78
	Granted			715			8.45			247			0.35		5			3.5
	Exercised			(61	)		3.24			—			—		—			—
	Terminated			(10	)		3.5			—			—		(5	)		11.64
	Outstanding, end of year			1,024		$	6.21			380		$	1.45		133		$	3.5
	Exercisable, end of year			200						153					116
	Weighted average fair value of options granted during the year		$	6.18					$	0.21				$	1.75
	The following table summarizes information about stock options outstanding:
			At June 30,
	(Number of options in thousands; remaining		2014						2013
	lives in years)
	Exercise Price		Number of			Weighted			Number of			Weighted
			Options			Average			Options			Average
						Contractual Life						Contractual Life
						Remaining						Remaining
	$  0.35			242			8.53			247			9.53
	$  3.50			67			4.74			133			4.49
	$  4.90			403			9.23			—			—
	$12.00			157			9.74			—			—
	$14.08			155			9.8			—			—
				1,024						380
	The following table summarizes information about stock options exercisable:
			At June 30,
			2014			2013
	Exercise Price		Number of Options
			(in thousands)
	$  0.35			83			71
	$  3.50			64			82
	$  4.90			47			—
	$12.00			—			—
	$14.08			6			—
				200			153
	As of June 30, 2014, the aggregate intrinsic value of all outstanding stock options was $17.3 million and for exercisable stock options was $4.0 million. The intrinsic value per option at June 30, 2014 is calculated as the difference between the exercise price of the underlying option and the closing price of the Company’s common stock of $23.10 on that date. The total fair value of options that vested during the fiscal years ended June 30, 2014, 2013, and 2012 was $280 thousand, $43 thousand, and $37 thousand, respectively.
	Unrecognized compensation expense related to non-vested employee stock options amounted to $3.4 million as of June 30, 2014. Such compensation expense is expected to be recognized over a weighted-average period of 3.2 years.
	In accounting for stock options to non-employees, the value of goods and services related to the options granted are recognized as the awards vest, which is generally consistent with receipt of services. Therefore, vested portions vary based upon services and terms of each option. The Company revalues non-vested, non-employee options each reporting period using the estimated fair value of the Company’s common stock as of the last day of each reporting period.
	Share-based expense related to stock options awarded to employees, non-employee directors and consultants amounted to $825 thousand, $25 thousand and $24 thousand for the fiscal years ended June 30, 2014, 2013 and 2012, respectively. The expense was allocated as follows:
			For the fiscal years
			ended June 30,
	(In thousands)		2014			2013			2012
	Research and development		$	77		$	11		$	9
	General and administrative			748			14			15
			$	825		$	25		$	24
	The fair value of each option granted is estimated on the grant date using the Black-Scholes stock option pricing model. The following assumptions were made in estimating fair value:
			Fiscal Years Ended
			June 30,
	Assumption		2014			2013			2012
	Dividend yield			0	%		0	%		0	%
	Expected term			6.00 to 10.00 years			6.25 to 10.00 years			6.25 years
	Risk-free interest rate			2.04% to 2.31	%		1.37% to 1.40	%		1.39	%
	Expected volatility			85	%		63.23	%		65.02	%
	The dividend yield is based upon the assumption that the Company will not declare a dividend over the life of the options. Since adopting ASC 718, the Company has been unable to use historical employee exercise and option expiration data to estimate the expected term assumption for the Black-Scholes grant-date valuation. The Company therefore has utilized the “simplified” method, as prescribed by the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment, to estimate on a formula basis the expected term of our stock options considered to have “plain vanilla” characteristics. The risk-free interest rate is based on the U.S. Treasury yield curve on the date of the grant. As a new public company, the Company does not have sufficient history to estimate the volatility of its common stock price or the expected life of the options. The Company calculates expected volatility based on reported data for similar publicly traded companies for which historical information is available and will continue to do so until the historical volatility of its common stock is sufficient to measure expected volatility for future option grants. The group of similar publicly traded companies was determined based upon companies considered to be direct competition or having been presented by independent parties as a “comparable” company based upon market sector. In determining this group, the Company has excluded “large-cap” entities. Forfeitures are estimated at the time of the grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation expense recognized in the statements of operations for the fiscal years ended June 30, 2014, 2013 and 2012 does not record tax related effects on stock-based compensation given the Company’s historical and anticipated operating losses and offsetting changes in its valuation allowance that fully reserves against potential deferred tax assets.
	The fair value of the shares of common stock that underlie the stock options the Company has granted has historically been determined by the Company’s board of directors based upon information available to it at the time of grant. The Company’s board of directors considered numerous objective and subjective factors in the assessment of fair value, including reviews of the Company’s business and financial condition, the conditions of the industry in which the Company operates and the markets that the Company serves and general economic, market and United States and global capital market conditions, the lack of marketability of its common stock, the likelihood of achieving a liquidity event for the shares of common stock underlying these stock options, the preferences and privileges of the preferred stock over the rights of the common stock, the status of the clinical trials and preclinical studies relating to its product candidates and third-party valuations of its common stock. The Company’s board has generally considered the most persuasive evidence of fair value to be the prices at which the Company’s securities were sold in actual arms’ length transactions. Following its IPO, the Company’s shares of common stock are now traded on the Nasdaq Global Select Market and it is no longer required to estimate the fair value of common stock underlying new equity awards.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments and Investments	12 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments and Investments	'
	-6	Fair Value of Financial Instruments and Investments:
	The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis:
	Description		Total			Quoted prices			Significant other		Significant
						in active markets			observable inputs		unobservable inputs
						(Level 1)			(Level 2)		(Level 3)
	Assets:
	June 30, 2014
	Short-term investments		$	64,450		$	—		$	64,450	$	—
	June 30, 2013
	Short-term investments		$	14,000		$	—		$	14,000	$	—
	Liabilities:
	June 30, 2013
	Series B purchase rights		$	2,096		$	—		$	—	$	2,096
	Warrant liabilities			110			—			—		110
	Total		$	2,206		$	—		$	—	$	2,206
	Short-term investments
	Short-term investments consist of certificates of deposit placed through an account registry service, with maturities up to one year, for which the fair market value is measured based on level 2 inputs (quoted prices for identical assets in markets that are not active).
	Warrant liabilities
	As of June 30, 2013, we had warrants outstanding to purchase shares of our Series A-1, Series A-1A and Series B-1 preferred stock. Because our Series A-1, Series A-1A and Series B-1 preferred stock were subject to redemption under circumstances outside of our control, the outstanding shares of these series of preferred stock are presented as temporary equity for those periods. Consequently, the warrants to purchase shares of Series A-1, Series A-1A and Series B-1 preferred stock were accounted for as liabilities and adjusted to fair value at the end of each reporting period. The fair value of the warrants classified as liabilities was estimated using the Black-Scholes option pricing model. The estimates in the Black-Scholes option pricing model were based, in part, on subjective assumptions, including stock price volatility, term of the warrants, risk free interest rate, dividend yield, and fair value of the preferred stock underlying the warrants. The gain or loss associated with the change in the fair value of the preferred stock warrant liability from the prior period was recognized as a component of other (expense) income, net. The fair value of the warrants on the date of issuance, and on each financial reporting date for those warrants classified as liabilities, was estimated using the Black-Scholes option pricing model.
	The significant assumptions used in preparing the option pricing model for valuing the Company’s warrants include:
			For the years ended June 30,
	Assumption		2014		2013	2012
	Exercise price		$0.13 to $0.97		$0.13 to $0.97	$0.13 to $0.97
	Fair value of preferred shares		$0.23 to $0.90		$0.15	$0.13
	Expected life (in years)		0.12 to 5.67		0.26 to 7.00	1.26 to 7.17
	Risk-free interest rate		0.01% to 1.75%		0.07% to 1.69%	0.27% to 1.39%
	Expected volatility		70.00% to 85.00%		63.23%	65.02%
	Upon the closing of our initial public offering, these warrants were converted into warrants exercisable for common stock.
	Series B purchase rights
	In November 2012, we entered into a Series B-1, B-2 and B-3 Preferred Stock Purchase Agreement, or Series B Purchase Agreement, which authorized the sale of up to 290,781,972 shares of convertible preferred stock in three separate tranches of Series B-1, Series B-2 and Series B-3 preferred stock, respectively. Simultaneously with the execution of the Series B Purchase Agreement, we issued and sold an aggregate of 66,147,709 shares of Series B-1 preferred stock at a price per share of $0.1297. The Series B Purchase Agreement provided that the holders of the Series B-1 shares, or Series B holders, were also entitled to purchase up to an aggregate of 140,542,178 shares of Series B-2 preferred stock for an aggregate purchase price equal to $18.2 million, or second tranche, and up to an aggregate of 82,670,167 shares of Series B-3 preferred stock for an aggregate purchase price equal to $10.7 million, or third tranche. The price per share and number of shares to be issued in exchange for such amount was to be determined separately for each tranche by reference to which, if any, of three milestones specified in the agreement had been satisfied by us.
	The purchase rights were legally separable and exercisable apart from the Series B-1 shares and, because representatives of the Series B holders hold a majority of the seats on the board of directors, the decision to complete the second and third tranche was deemed to be outside our control. We therefore recorded, at the time of entry into the Series B Purchase Agreement, a Series B purchase rights liability of $1.7 million for the fair value of our obligation to sell the Series B-2 and Series B-3 preferred stock in the second and third tranche. The Series B purchase rights liability was valued separately for each series using the Black-Scholes option-pricing method to assign a value to the purchase right relating to that series under each of the possible applicable valuation scenarios, depending on which milestones were met, with each scenario being assigned an estimated probability as of the valuation date. The aggregate of these probability-weighted valuations was assigned as the value of the purchase right for each tranche. The initial fair value of the Series B purchase rights liability was estimated to be $0.6 million for the second tranche and $1.1 million for the third tranche. The total value allocated to the Series B purchase rights reduced the amount allocated to the carrying value of the Series B-1 preferred stock on our balance sheet.
	The most significant and judgmental inputs driving the fair value of our Series B purchase rights are the assumptions regarding the fair value of the underlying preferred shares and the volatility factor. With all other inputs constant, an increase or decrease in the assumed fair value of the preferred shares would result in a higher or lower estimate of the fair value of the Series B purchase rights, respectively, although there would not be a direct correlation. Similarly, an increase or decrease in the assumed volatility factor would result in a higher or lower estimate of the fair value of the Series B purchase rights, respectively.
	In April 2013, following the satisfaction by us of the first milestone, the Series B holders exercised their rights with respect to the second tranche and purchased an aggregate of 122,749,639 shares of Series B-2 preferred stock at a price per share of $0.1485, for gross cash proceeds of $18.2 million. During fiscal year 2013, we recorded a change in value of the Series B purchase rights liability of $1.2 million to other expense and the $0.8 million balance of the value allocated to the Series B-2 purchase rights liability immediately prior to the closing of the second tranche was recorded as proceeds from the issuance of the Series B-2 preferred stock.
	In October 2013, the Series B holders exercised their rights with respect to the third tranche and on November 5, 2013, we sold to the Series B holders an aggregate of 58,816,897 shares of our Series B-3 preferred stock at a price per share of $0.1823 (or $6.38 on an as-converted to common stock basis), for gross cash proceeds of $10.7 million. In connection with the closing of the third tranche, we and the Series B holders amended the terms of the Series B purchase agreement to provide that if the two remaining milestones specified in the Series B Purchase Agreement are not satisfied by September 2014, the Series B holders who continue to hold shares of Series B-3 preferred stock will be entitled to receive an aggregate of approximately 13,387,000 additional shares of Series B-3 preferred stock. This right was extinguished upon the conversion to common stock of all outstanding shares of our preferred stock upon the closing of our initial public offering.
	During the year ended June 30, 2014, we recorded a change in value of the Series B purchase right liability of $2.9 million to other expense, and $5.0 million allocated to the Series B-3 purchase right immediately prior to the closing of the third tranche was reallocated to the carrying value of the Series B-3 preferred stock.
	The significant assumptions used as inputs in the Black-Scholes valuation were as follows:
			For the years ended June 30,
	Assumption		2014		2013
	Exercise price		$0.15 to $0.18		$0.15 to $0.18
	Years to maturity		0.00 to 1.00		0.08 to 1.87
	Risk-free interest rate		0.06% to 0.10%		0.04% to 0.25%
	Expected volatility		55.00% to 85.00%		55.00% to 60.00%
	The Company reports the change in fair value during each period as a non-operating gain or loss recorded as a component of other (expense) income, net in the statement of operations. The table presented below is a summary of changes in the fair value of the Company’s Level 3 valuation for warrant liabilities and Series B purchase rights for the fiscal years ended June 30, 2014, 2013 and 2012:
			Warrant			Series B
			liabilities			purchase
						rights
	Beginning balance as of July 1, 2011		$	205		$	—
	Fair value of warrants issued			79			—
	Change in fair value during the period			(204	)		—
	Ending balance as of June 30, 2012			80			—
	Fair value of warrants issued			22			—
	Fair value of Series B purchase rights issued			—			1,723
	Change in fair value during the period			8			1,207
	Series B purchase rights converted to Series B-2 convertible preferred stock			—			(834	)
	Ending balance as of June 30, 2013			110			2,096
	Change in fair value during the period			441			2,904
	Preferred Stock Warrants converted to Warrants for Common Stock			(551	)		—
	Series B purchase rights converted to Series B-3 convertible preferred stock			—			(5,000	)
	Ending balance as of June 30, 2014		$	—		$	—

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	-7	Commitments and Contingencies:
	Operating leases—The Company leases office equipment, office space, and lab space under operating leases expiring through December 2014. For the fiscal years ended June 30, 2014, 2013 and 2012, rent expense under these and other operating leases was $123 thousand, $102 thousand and $82 thousand, respectively. Minimum future lease payments (in thousands) under non-cancelable operating leases as of June 30, 2014 in the aggregate are:
	Fiscal Year Ending June 30,		Amount
	2015		$	72
	Total minimum future lease payments		$	72
	Other contingencies—Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with various not-for-profit organizations. The Company may become obligated to pay royalties on net product sales of any collaboration product that it successfully develops and subsequently commercializes or, if it out-licenses rights to a collaboration product, a specified percentage of certain payments it receives from its licensee. The Company is not obligated to make such payments unless and until annual sales of a collaboration product exceed a designated threshold. The Company’s obligation to make such payments would end upon its payment of a specified amount.
	The Company is also party to various agreements entered into in the ordinary course of its business, principally relating to licensed technology, that require future payments relating to milestones or royalties on future sales of specified products. At June 30, 2014, the Company had nine license agreements with six different entities, including five with the University of Florida Research Foundation. Several of these entities are stockholders of the Company. The Company is required to pay minimum annual royalty and license maintenance for all licenses until such time when the license is terminated by either expiration of underlying patents or voluntary termination by either party per the agreement. Once a product reaches commercialization, the above-mentioned minimum annual payments will be replaced by annual royalties ranging from 0.5% to 4.0% on net sales. The Company is responsible for all costs related to preparation, filing, issuance, prosecution and maintenance of the underlying patents covered in the license agreements. As of June 30, 2014, the Company held one license where certain milestones requiring additional royalty payments had been met. The Company may terminate its license agreements with zero to ninety days written notice depending upon the terms of each specific agreement. The Company paid annual royalty and license maintenance payments of $87 thousand, $61 thousand and $41 thousand for each of the fiscal years ended June 30, 2014, 2013 and 2012, respectively. All royalty and license maintenance payments are included within research and development expenses in the statement of operations.
	Minimum annual royalty and license maintenance payments (in thousands) under these agreements are as follows:
	Fiscal Year Ending June 30,		Amount
	2015		$	89
	2016		$	151
	2017		$	152
	2018 and every fiscal year thereafter		$	156
	The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company’s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company’s products. The term of these indemnification agreements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. From time to time, the Company is involved in various claims and legal actions that arise in the normal course of business. Management believes that the outcome of such legal actions will not have a significant adverse effect on the Company’s financial position, results of operations or cash flows.

Concentrations

Concentrations	12 Months Ended
	Jun. 30, 2014
Risks And Uncertainties [Abstract]	'
Concentrations	'
	-8	Concentrations:
	The Company has demand deposits and money market funds in a regional bank that are insured by the FDIC up to FDIC limits. In addition, the Company has short-term investments in certificates of deposits at various financial institutions that are 100% FDIC insured.
	All of the Company’s grant receivables at June 30, 2014 and 2013 are derived from or associated with government and sponsored research grants. Any future changes in the availability of grants for such research would have a significant impact on the Company’s operations.

Income_Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	-9	Income Taxes:
	For the fiscal years ended June 30, 2014, 2013 and 2012, the Company did not record a current or deferred income tax expense or benefit.
	Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets (liabilities) are comprised of the following:
			At June 30,
	In thousands		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards		$	22,661		$	18,041
	Research and development credit carryforwards			1,262			888
	Accruals and other			238			111
	Gross deferred tax assets			24,161			19,040
	Deferred tax asset valuation allowance			(24,086	)		(18,956	)
	Total deferred tax assets, net of valuation allowance			75			84
	Deferred tax liabilities:
	Depreciation and amortization			(75	)		(84	)
	Total deferred tax liabilities			(75	)		(84	)
	Net deferred tax asset (liability)		$	—		$	—
	At June 30, 2014, the Company has net operating losses of approximately $58.7 million that may be applied against future taxable income and expire in various years from 2022 to 2034. At June 30, 2014, the Company also has research and development tax credits of approximately $1.3 million that may provide future tax benefits and expire from 2027 to 2043.
	The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company’s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Therefore, any tax benefits to be realized in future years as a result of the utilization of the Company’s net operating loss carry forwards as of June 30, 2014, computed based on statutory federal and state rates, are completely offset by valuation allowances established because realization of the deferred tax benefits are not considered more likely than not. The valuation allowance increased by approximately $5.1 million during the fiscal year ended June 30, 2014, due primarily to net operating losses generated during the period.
	A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows:
			For the years ended
			June 30,
			2014			2013			2012
	Federal income tax benefit at statutory rate			(34	)%		(34	)%		(34	)%
	State income tax, net of federal benefit			(4	)%		(4	)%		(4	)%
	Permanent differences			9	%		11	%		(3	)%
	Research and development credit			(2	)%		(3	)%		(7	)%
	Other			1	%		2	%		3	%
	Change in valuation allowance			30	%		28	%		45	%
	Effective income tax rate			0	%		0	%		0	%
	Under the provisions of the Internal Revenue Code, the Company’s net operating loss and tax credit carry forwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carry forwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50 percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future.
	For fiscal years through June 30, 2014, the Company generated research credits but has not conducted a study to document the qualified activities. This study may result in an adjustment to the Company’s research and development credit carry forwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position at June 30, 2014 and 2013. A full valuation allowance has been provided against the Company’s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carry forwards and the valuation allowance.
	The Company files income tax returns in the United States and in the state of Florida. The federal and state returns are generally subject to tax examinations for the tax years ended June 30, 2010 through June 30, 2014. To the extent the Company has tax attribute carry forwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, or state authorities, to the extent such attributes are utilized in a future period.
	The Company’s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of June 30, 2014 and 2013, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statements of operations for any of the fiscal years ended June 30, 2014, 2013 and 2012.

Convertible_Preferred_Stock_an

Convertible Preferred Stock and Stockholders' Equity (Deficit)	12 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Convertible Preferred Stock and Stockholders' Equity (Deficit)	'
	-10	Convertible Preferred Stock and Stockholders’ Equity (Deficit):
	On April 1, 2014, the Company completed its IPO in which it sold 4,166,667 shares of common stock at a price of $12.00 per share. The shares began trading on the Nasdaq Global Select Market on March 27, 2014. An additional 625,000 shares were sold pursuant to the exercise of the underwriters’ over-allotment option, also at the offering price of $12.00 per share. The aggregate net proceeds received by the Company from the offering, including exercise of the over-allotment option, amounted to $51.6 million, net of underwriting discounts and commissions and other issuance costs incurred by the Company. Upon the closing of the IPO, all outstanding shares of convertible preferred stock converted into 9,120,081 shares of common stock; and warrants exercisable for convertible preferred stock were automatically converted into warrants exercisable for 49,811 shares of common stock, resulting in the reclassification of the related convertible preferred stock warrant liability of $551 thousand to additional paid-in capital.
	Convertible Preferred Stock
	The Company’s convertible preferred stock at June 30, 2013 is summarized below:
			At June 30, 2013
	In thousands		Shares		Shares		Carrying Value
			Authorized		Issued and
					Outstanding
	Series A-1			29,737		22,466	$	21,526
	Series A-1A			11,572		11,479		10,998
	Series B-1			67,570		66,147		6,539
	Series B-2			140,542		122,750		19,040
	Series B-3			82,670		—		—
	Total			332,091		222,842	$	58,103
	In November 2013, the Company issued and sold an additional 58,816,897 aggregate shares of Series B-3 preferred stock at a price per share of $0.1823. See Note 6 for further discussion of this transaction.
	In connection with the consummation of the Company’s IPO, on April 1, 2014, all of the above-mentioned outstanding shares of the Company’s convertible preferred stock converted into 9,120,081 shares of its common stock. As a result, none of these convertible series of preferred stock were issued nor outstanding at June 30, 2014. The Company also amended and restated its Certificate of Incorporation to decrease the number of shares of preferred stock authorized to be issued to 5,000,000 shares of $0.001 par value preferred stock, of which none were outstanding as of June 30, 2014.
	Common Stock
	As of June 30, 2012, the Company’s common stock consisted of 45,102,000 authorized shares. In November 2012, the Company amended and restated its Certificate of Incorporation to increase the number of shares common stock authorized to be issued to 410,000,000 shares of $0.001 par value common stock.
	On March 4, 2014, the Company effected a 1-for-35 reverse stock split of its common stock, whereby each share of common stock, $0.001 par value, outstanding immediately prior to that date was combined, reclassified and changed into one thirty-fifth (1/35) of a fully paid and non-assessable share of common stock. All common share and common per share information in the accompanying financial statements has been retroactively adjusted to reflect the reverse stock split and adjustment of the preferred stock conversion ratios for all periods presented. In connection with the Company’s IPO, on April 1, 2014, the Company amended and restated its Certificate of Incorporation to decrease the number of shares of common stock authorized to be issued to 150,000,000 shares of $0.001 par value common stock.
	The following shares of common stock are reserved for future issuance:
	In thousands		June 30, 2014
	Common stock warrants			50
	Stock options issued and outstanding			1,024
	Authorized for future grant under the 2013 Equity and Incentive Plan			839
				1,913

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Jun. 30, 2014
Payables And Accruals [Abstract]	'
Accrued Expenses	'
	-11	Accrued Expenses:
	Accrued expenses consist of the following:
			At June 30,
	In thousands		2014		2013
	Research and development-related		$	1,008	$	61
	Compensation-related			575		298
	Other			2		1
			$	1,585	$	360

Defined_Contribution_Plan

Defined Contribution Plan	12 Months Ended
	Jun. 30, 2014
Compensation And Retirement Disclosure [Abstract]	'
Defined Contribution Plan	'
	-12	Defined Contribution Plan:
	The Company sponsors a 401(k) Plan (the “Plan”) that covers substantially all of its employees and is administered through its staff leasing company. Under the Plan, employees may elect to defer up to 25% of their compensation and the Company matches a portion of such employee contributions up to a maximum of 4%. Total employer contributions to the Plan for the fiscal years ended June 30, 2014, 2013 and 2012 were approximately $60 thousand, $40 thousand and $34 thousand, respectively.

Quarterly_Financial_Informatio

Quarterly Financial Information	12 Months Ended
	Jun. 30, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information	'
	-13	Quarterly Financial Information (Unaudited):
	Summarized quarterly information for the two fiscal years ended June 30, 2014 and 2013, respectively, is as follows:
			Fiscal Year 2014 by Quarter:
	In thousands, except per share data		First			Second			Third			Fourth
	Revenue		$	258		$	515		$	232		$	124
	Loss from operations		$	(1,966	)	$	(2,905	)	$	(3,260	)	$	(4,425	)
	Net loss		$	(7,064	)	$	(735	)	$	(3,588	)	$	(4,521	)
	Net loss per common share, basic and diluted		$	(64.81	)	$	(6.74	)	$	(25.45	)	$	(0.32	)
			Fiscal Year 2013 by Quarter:
	In thousands, except per share data		First			Second			Third			Fourth
	Revenue		$	259		$	190		$	116		$	377
	Loss from operations		$	(560	)	$	(796	)	$	(951	)	$	(1,287	)
	Net loss		$	(604	)	$	(1,336	)	$	(1,622	)	$	(1,428	)
	Net loss per common share, basic and diluted		$	(5.54	)	$	(12.26	)	$	(14.88	)	$	(13.10	)

Subsequent_Events

Subsequent Events	12 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	-14	Subsequent Events:
	On July 30, 2014, the Company completed a public offering in which the Company sold 2,000,000 shares of common stock at a public offering price of $15.00 per share. On August 1, 2014, the Company sold an additional 300,000 shares of common stock at a public offering price of $15.00 per share pursuant to the full exercise of an overallotment option granted to the underwriters in connection with the public offering that was completed in July 2014. The aggregate net proceeds received by the Company from the offering, including the exercise of the overallotment option, amounted to $32.0 million, net of underwriting discounts and commissions.

Schedule_IIValuation_and_Quali

Schedule II-Valuation and Qualifying Accounts	12 Months Ended
	Jun. 30, 2014
Valuation And Qualifying Accounts [Abstract]	'
Schedule II-Valuation and Qualifying Accounts	'
	SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
				Additions
	In thousands	Beginning		Charge		To (from)		Deductions		End of
		of Period		(Benefit) to		Other				Period
				Expenses		Accounts
	Deferred Tax Valuation Allowance
	Year 2014	$	18,956	$	5,130	$	—	$	—	$	24,086
	Year 2013	$	17,468	$	1,488	$	—	$	—	$	18,956
	Year 2012	$	16,487	$	981	$	—	$	—	$	17,468

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	(a)	Basis of Presentation—The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
Segment Reporting	'
	(b)	Segment Reporting—The Company operates in only one segment. The chief operating decision-maker and management use cash flows as the primary measure to manage the business and do not segment the business for internal reporting or decision making.
Use of estimates	'
	(c)	Use of estimates —The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and cash equivalents	'
	(d)	Cash and cash equivalents—The Company considers all highly liquid investments with a maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks and money market accounts. Cash equivalents are carried at cost, which approximates fair value due to their short-term nature.
Short-term investments	'
	(e)	Short-term investments—The Company considers all investments with a maturity of 91 to 360 days at the time of purchase to be short-term investments. Short-term investments, which include certificates of deposit maturing within 91 to 360 days of date of purchase, are carried at cost which approximates their fair value due to their short-term nature.
Inventory	'
	(f)	Inventory—The Company expenses costs for clinical materials stored for master and working viral banks that remain at the sites in anticipation of their future use at that site. Since the Company can use each of the raw materials in only a single product, each raw material is deemed to have no future economic value independent of the development status of that single drug.
Fair value of financial instruments	'
		(g)	Fair value of financial instruments—The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures (“ASC 820”), establishes a hierarchy of inputs used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of financial instruments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:
	Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
	Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and observable.
	To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	Items measured at fair value on a recurring basis include short-term investments, Series B purchase rights and warrant liabilities (See Note 6).
Property and equipment	'
	(h)	Property and equipment—Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which are generally three to seven years. The Company periodically enters into service contracts with independent third parties for the maintenance on some of its major laboratory equipment. The maintenance contracts are generally prepaid and the Company recognizes the expense over the terms of such contracts, usually twelve months or less.
Intangible assets	'
		(i)	Intangible assets—Intangible assets include licenses and patents. The Company obtains licenses from third parties and capitalizes the costs related to exclusive licenses that have alternative future use in multiple potential programs. The Company also capitalizes costs related to filing, issuance, and prosecution of patents. The Company reviews its capitalized costs periodically to determine that costs recorded include costs for patent applications that have future value. The Company evaluates costs related to patents that it is not actively pursuing and writes off any of these costs. Amortization expense is computed using the straight-line method over the estimated useful lives of the assets, which are generally eight to twenty years. The Company amortizes in-licensed patents and patent applications from the date of the applicable license and internally developed patents and patent applications from the date of the initial application. Licenses and patents converted to research use only are expensed immediately.
Impairment of long-lived assets	'
	(j)	Impairment of long-lived assets—The Company reviews its long-lived assets for impairment when impairment indicators are present. If impairment indicators exist, management determines whether impairment in value has occurred by comparing the estimated undiscounted cash flows from future operations with the carrying values of the assets. Management considers several indicators in assessing impairment, including trends and prospects, as well as the effects of obsolescence, demand, competition and other economic factors. For the fiscal years ended June 30, 2014, 2013, and 2012, the Company did not identify any indicators of impairment for its long-lived assets. The Company has not yet generated positive cash flows, and such cash flows may not materialize for a significant period in the future. As a result, it is reasonably possible that future evaluations of long-lived assets may result in a conclusion that such assets have been impaired.
Warrants to purchase convertible preferred stock	'
	(k)	Warrants to purchase convertible preferred stock—In conjunction with various financing transactions, the Company issued warrants to purchase shares of its Series A-1, Series A-1A and Series B-1 preferred stock. Prior to the consummation of the Company’s IPO, the Company’s Series A-1, Series A-1A and Series B-1 preferred stock were subject to redemption under circumstances outside of the Company’s control. Therefore, for periods prior to the consummation of the IPO, the associated shares are presented as temporary equity. Consequently, for those periods, the warrants to purchase shares of Series A-1, Series A-1A and Series B-1 preferred stock were accounted for as liabilities and adjusted to fair value at the end of each reporting period. The fair value of the warrants classified as liabilities was estimated using the Black-Scholes option pricing model. The estimates in the Black-Scholes option pricing model were based, in part, on subjective assumptions, including stock price volatility, term of the warrants, risk free interest rate, dividend yield, and fair value of the preferred stock underlying the warrants. The gain or loss associated with the change in the fair value of the preferred stock warrant liability from the prior period is recognized as a component of other (expense) income, net.
Revenue recognition	'
		(l)	Revenue recognition—The Company has primarily generated revenue through collaboration agreements, sponsored research arrangements with nonprofit organizations for the development and commercialization of product candidates and revenues from federal research and development grant programs. The Company recognizes revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price is fixed or determinable; and (4) collection of the amounts due are reasonably assured.
	Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current liabilities. The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses, as the Company has the risks and rewards as the principal in the research and development activities.
	The Company evaluates the terms of sponsored research agreement grants and federal grants to assess the Company’s obligations and if the Company’s obligations are satisfied by the passage of time, revenue is recognized on a straight-line basis. In situations where the performance of the Company’s obligations has been satisfied when the grant is received, revenue is recognized upon receipt of the grant. Certain grants contain refund provisions. The Company reviews those refund provisions to determine the likelihood of repayment. If the likelihood of repayment of the grant is determined to be remote, the grant is recognized as revenue. If the probability of repayment is determined to be more than remote, the Company records the grant as a deferred revenue liability, until such time that the grant requirements have been satisfied.
Income taxes	'
		(m)	Income taxes—The Company uses the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
	As required by U.S. GAAP, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company files income tax returns in the U.S. federal jurisdiction and the state of Florida. As of June 30, 2014 and 2013, the Company did not have any significant uncertain tax positions.
Research and development	'
	(n)	Research and development—Research and development costs include costs incurred in identifying, developing and testing product candidates. Costs consist primarily of payroll expenses for research related employees, laboratory costs, animal and laboratory maintenance and supplies, rent, utilities, clinical and pre-clinical expenses, as well as payments for sponsored research, scientific and regulatory consulting fees and testing. Costs are charged to expense as incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites. When outside contracts for research products or testing require advance payments, these payments are recorded on the balance sheet as a prepaid expense and subsequently recognized as an operating expense when the service is provided or when a specific milestone outlined in the contract is reached. Advance payments related to research and development were $1.4 million and $444 thousand at June 30, 2014 and 2013, respectively, and are included in other current assets on the balance sheets.
Share-based compensation	'
		(o)	Share-based compensation—The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the award. That cost is recognized on a straight-line basis over the period during which the employee is required to provide service in exchange for the award. The fair value of options on the date of grant is calculated using the Black-Scholes option pricing model based on key assumptions such as stock price (prior to April 2014 IPO), expected volatility and expected term. The Company’s estimates of these assumptions are primarily based on third-party valuations historical data, peer company data and judgment regarding future trends and factors. The Company accounts for stock options issued to non-employees in accordance with the provisions of ASC Subtopic 505-50, Equity-Based Payments to Non-employees, which requires valuing the stock options and measuring such stock options to their current fair value when they vest. Refer to Note 5 for details regarding the Company’s share-based compensation plans.
Net loss per share	'
	(p)	Net loss per share—Basic net loss per share is calculated by dividing net loss by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, preferred stock, stock options, and warrants are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share was the same for all periods presented.
Comprehensive loss	'
	(q)	Comprehensive loss—Comprehensive loss consists of net loss and changes in equity during a period from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all periods presented.
New Accounting Pronouncements	'
	(r)	New Accounting Pronouncements—In May 2014, the FASB issued guidance that requires companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. It also requires enhanced disclosures about revenue, provides guidance for transactions that were not previously addressed comprehensively, and improves guidance for multiple-element arrangements. The guidance applies to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. The guidance is effective for public companies for annual periods beginning after December 15, 2016 as well as interim periods within those annual period using either the full retrospective approach or modified retrospective approach. Early adoption is not permitted. The Company is currently evaluating the impacts of the new guidance on its financial statements.

Property_and_Equipment_Net_Tab

Property and Equipment, Net (Tables)	12 Months Ended
	Jun. 30, 2014
Property Plant And Equipment [Abstract]	'
Components of Property and Equipment	'
	Property and equipment consists of the following:
		At June 30,
	In thousands	2014			2013
	Laboratory equipment	$	1,085		$	945
	Office equipment		92			79
	Leasehold improvements		8			8
	Software		41			32
	Property and equipment, gross		1,226			1,064
	Less: Accumulated depreciation and amortization		(824	)		(723	)
	Property and equipment, net	$	402		$	341

Intangible_Assets_Net_Tables

Intangible Assets, Net (Tables)	12 Months Ended
	Jun. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets Subject to Amortization	'
	Intangible assets subject to amortization consist of the following:
		At June 30, 2014
	In thousands	Cost		Accumulated		Net of
				Amortization		Accumulated
						Amortization
	Licenses	$	1,143	$	751	$	392
	Patents		1,892		719		1,173
	Intangible assets, net	$	3,035	$	1,470	$	1,565
		At June 30, 2013
	In thousands	Cost		Accumulated		Net of
				Amortization		Accumulated
						Amortization
	Licenses	$	1,080	$	672	$	408
	Patents		1,791		569		1,222
	Intangible assets, net	$	2,871	$	1,241	$	1,630
Schedule of Estimated Amortization Expense	'
	Estimated amortization expense for the next five years and thereafter is as follows:
	Fiscal Year Ending June 30,	Amount
	2015	$	234
	2016		222
	2017		219
	2018		210
	2019		169
	Thereafter		511
		$	1,565

Sharebased_Compensation_Plans_

Share-based Compensation Plans (Tables)	12 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Stock Option Activity	'
	A summary of the stock option activity is as follows:
		For the years ended June 30,
		2014						2013					2012
	(In thousands, except per share amounts)	Shares			Weighted			Shares			Weighted		Shares			Weighted
					Average						Average					Average
					Exercise						Exercise					Exercise
					Price						Price					Price
	Outstanding, beginning of year		380		$	1.45			133		$	3.5		133		$	3.78
	Granted		715			8.45			247			0.35		5			3.5
	Exercised		(61	)		3.24			—			—		—			—
	Terminated		(10	)		3.5			—			—		(5	)		11.64
	Outstanding, end of year		1,024		$	6.21			380		$	1.45		133		$	3.5
	Exercisable, end of year		200						153					116
	Weighted average fair value of options granted during the year	$	6.18					$	0.21				$	1.75
Summary of Stock Options Outstanding and Exercisable	'
	The following table summarizes information about stock options outstanding:
		At June 30,
	(Number of options in thousands; remaining	2014						2013
	lives in years)
	Exercise Price	Number of			Weighted			Number of			Weighted
		Options			Average			Options			Average
					Contractual Life						Contractual Life
					Remaining						Remaining
	$  0.35		242			8.53			247			9.53
	$  3.50		67			4.74			133			4.49
	$  4.90		403			9.23			—			—
	$12.00		157			9.74			—			—
	$14.08		155			9.8			—			—
			1,024						380
	The following table summarizes information about stock options exercisable:
		At June 30,
		2014			2013
	Exercise Price	Number of Options
		(in thousands)
	$  0.35		83			71
	$  3.50		64			82
	$  4.90		47			—
	$12.00		—			—
	$14.08		6			—
			200			153
Summary of Allocation of Share Based Compensation	'
	The expense was allocated as follows:
		For the fiscal years
		ended June 30,
	(In thousands)	2014			2013			2012
	Research and development	$	77		$	11		$	9
	General and administrative		748			14			15
		$	825		$	25		$	24
Stock Option Pricing Model Assumption	'
	The following assumptions were made in estimating fair value:
		Fiscal Years Ended
		June 30,
	Assumption	2014			2013			2012
	Dividend yield		0	%		0	%		0	%
	Expected term		6.00 to 10.00 years			6.25 to 10.00 years			6.25 years
	Risk-free interest rate		2.04% to 2.31	%		1.37% to 1.40	%		1.39	%
	Expected volatility		85	%		63.23	%		65.02	%

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments and Investments (Tables)	12 Months Ended
	Jun. 30, 2014
Schedule of Major Category of Company's Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis:
	Description	Total			Quoted prices			Significant other		Significant
					in active markets			observable inputs		unobservable inputs
					(Level 1)			(Level 2)		(Level 3)
	Assets:
	June 30, 2014
	Short-term investments	$	64,450		$	—		$	64,450	$	—
	June 30, 2013
	Short-term investments	$	14,000		$	—		$	14,000	$	—
	Liabilities:
	June 30, 2013
	Series B purchase rights	$	2,096		$	—		$	—	$	2,096
	Warrant liabilities		110			—			—		110
	Total	$	2,206		$	—		$	—	$	2,206
Summary of Changes in Fair Value of Company's Level 3 Valuation for Warrant Liabilities and Series B Purchase Rights	'
	The table presented below is a summary of changes in the fair value of the Company’s Level 3 valuation for warrant liabilities and Series B purchase rights for the fiscal years ended June 30, 2014, 2013 and 2012:
		Warrant			Series B
		liabilities			purchase
					rights
	Beginning balance as of July 1, 2011	$	205		$	—
	Fair value of warrants issued		79			—
	Change in fair value during the period		(204	)		—
	Ending balance as of June 30, 2012		80			—
	Fair value of warrants issued		22			—
	Fair value of Series B purchase rights issued		—			1,723
	Change in fair value during the period		8			1,207
	Series B purchase rights converted to Series B-2 convertible preferred stock		—			(834	)
	Ending balance as of June 30, 2013		110			2,096
	Change in fair value during the period		441			2,904
	Preferred Stock Warrants converted to Warrants for Common Stock		(551	)		—
	Series B purchase rights converted to Series B-3 convertible preferred stock		—			(5,000	)
	Ending balance as of June 30, 2014	$	—		$	—
Warrant liabilities [Member]	'
Schedule of Significant Assumptions Used for Valuation	'
	The significant assumptions used in preparing the option pricing model for valuing the Company’s warrants include:
		For the years ended June 30,
	Assumption	2014		2013	2012
	Exercise price	$0.13 to $0.97		$0.13 to $0.97	$0.13 to $0.97
	Fair value of preferred shares	$0.23 to $0.90		$0.15	$0.13
	Expected life (in years)	0.12 to 5.67		0.26 to 7.00	1.26 to 7.17
	Risk-free interest rate	0.01% to 1.75%		0.07% to 1.69%	0.27% to 1.39%
	Expected volatility	70.00% to 85.00%		63.23%	65.02%
Series B purchase rights [Member]	'
Schedule of Significant Assumptions Used for Valuation	'
	The significant assumptions used as inputs in the Black-Scholes valuation were as follows:
		For the years ended June 30,
	Assumption	2014		2013
	Exercise price	$0.15 to $0.18		$0.15 to $0.18
	Years to maturity	0.00 to 1.00		0.08 to 1.87
	Risk-free interest rate	0.06% to 0.10%		0.04% to 0.25%
	Expected volatility	55.00% to 85.00%		55.00% to 60.00%

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Minimum Future Lease Payments Under Non-Cancelable Operating Leases	'
	Minimum future lease payments (in thousands) under non-cancelable operating leases as of June 30, 2014 in the aggregate are:
	Fiscal Year Ending June 30,	Amount
	2015	$	72
	Total minimum future lease payments	$	72
Minimum Annual Royalty and License Maintenance Payments	'
	Minimum annual royalty and license maintenance payments (in thousands) under these agreements are as follows:
	Fiscal Year Ending June 30,	Amount
	2015	$	89
	2016	$	151
	2017	$	152
	2018 and every fiscal year thereafter	$	156

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Significant Components of Deferred Tax Assets (Liabilities)	'
	The significant components of the Company’s deferred tax assets (liabilities) are comprised of the following:
		At June 30,
	In thousands	2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	22,661		$	18,041
	Research and development credit carryforwards		1,262			888
	Accruals and other		238			111
	Gross deferred tax assets		24,161			19,040
	Deferred tax asset valuation allowance		(24,086	)		(18,956	)
	Total deferred tax assets, net of valuation allowance		75			84
	Deferred tax liabilities:
	Depreciation and amortization		(75	)		(84	)
	Total deferred tax liabilities		(75	)		(84	)
	Net deferred tax asset (liability)	$	—		$	—
Reconciliation of Income Tax Expense	'
	A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows:
		For the years ended
		June 30,
		2014			2013			2012
	Federal income tax benefit at statutory rate		(34	)%		(34	)%		(34	)%
	State income tax, net of federal benefit		(4	)%		(4	)%		(4	)%
	Permanent differences		9	%		11	%		(3	)%
	Research and development credit		(2	)%		(3	)%		(7	)%
	Other		1	%		2	%		3	%
	Change in valuation allowance		30	%		28	%		45	%
	Effective income tax rate		0	%		0	%		0	%

Convertible_Preferred_Stock_an1

Convertible Preferred Stock and Stockholders' Equity (Deficit) (Tables)	12 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Schedule of Convertible Preferred Stock	'
	The Company’s convertible preferred stock at June 30, 2013 is summarized below:
		At June 30, 2013
	In thousands	Shares		Shares		Carrying Value
		Authorized		Issued and
				Outstanding
	Series A-1		29,737		22,466	$	21,526
	Series A-1A		11,572		11,479		10,998
	Series B-1		67,570		66,147		6,539
	Series B-2		140,542		122,750		19,040
	Series B-3		82,670		—		—
	Total		332,091		222,842	$	58,103
Shares of Common Stock Reserved for Future Issuance	'
	The following shares of common stock are reserved for future issuance:
	In thousands	June 30, 2014
	Common stock warrants		50
	Stock options issued and outstanding		1,024
	Authorized for future grant under the 2013 Equity and Incentive Plan		839
			1,913

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Jun. 30, 2014
Payables And Accruals [Abstract]	'
Schedule of Accrued Expenses	'
	Accrued expenses consist of the following:
		At June 30,
	In thousands	2014		2013
	Research and development-related	$	1,008	$	61
	Compensation-related		575		298
	Other		2		1
		$	1,585	$	360

Quarterly_Financial_Informatio1

Quarterly Financial Information (Tables)	12 Months Ended
	Jun. 30, 2014
Quarterly Financial Information Disclosure [Abstract]	'
Summary of Quarterly Information	'
	Summarized quarterly information for the two fiscal years ended June 30, 2014 and 2013, respectively, is as follows:
		Fiscal Year 2014 by Quarter:
	In thousands, except per share data	First			Second			Third			Fourth
	Revenue	$	258		$	515		$	232		$	124
	Loss from operations	$	(1,966	)	$	(2,905	)	$	(3,260	)	$	(4,425	)
	Net loss	$	(7,064	)	$	(735	)	$	(3,588	)	$	(4,521	)
	Net loss per common share, basic and diluted	$	(64.81	)	$	(6.74	)	$	(25.45	)	$	(0.32	)
		Fiscal Year 2013 by Quarter:
	In thousands, except per share data	First			Second			Third			Fourth
	Revenue	$	259		$	190		$	116		$	377
	Loss from operations	$	(560	)	$	(796	)	$	(951	)	$	(1,287	)
	Net loss	$	(604	)	$	(1,336	)	$	(1,622	)	$	(1,428	)
	Net loss per common share, basic and diluted	$	(5.54	)	$	(12.26	)	$	(14.88	)	$	(13.10	)

Organization_and_Operations_Ad

Organization and Operations - Additional Information (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'	'
Initial public offering closing date	'2014-04-01	'
Accumulated deficit	($64,334,000)	($48,426,000)
Cash, cash equivalents and short-term investments	$73,100,000	'

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended			12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014
	Segment	Research and development-related [Member]	Research and development-related [Member]	Minimum [Member]	Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]	'	'	'	'	'
Number of operating segments	1	'	'	'	'
Property and equipment, estimated useful lives	'	'	'	'3 years	'7 years
Estimated useful life of intangible assets	'	'	'	'8 years	'20 years
Advance payments	'	$1,400	$444	'	'

Property_and_Equipment_Net_Com

Property and Equipment, Net - Components of Property and Equipment (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$1,226	$1,064
Less: Accumulated depreciation and amortization	-824	-723
Property and equipment, net	402	341
Laboratory equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	1,085	945
Office equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	92	79
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	8	8
Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$41	$32

Property_and_Equipment_Net_Add

Property and Equipment, Net - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Property, Plant and Equipment [Line Items]	'	'	'
Depreciation and amortization expense	$101	$64	$54
General and administrative [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Depreciation and amortization expense	14	14	10
Research and development-related [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Depreciation and amortization expense	$87	$50	$44

Intangible_Assets_Net_Schedule

Intangible Assets, Net - Schedule of Intangible Assets Subject to Amortization (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	$3,035	$2,871
Accumulated Amortization	1,470	1,241
Intangible assets, net	1,565	1,630
Licenses [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	1,143	1,080
Accumulated Amortization	751	672
Intangible assets, net	392	408
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	1,892	1,791
Accumulated Amortization	719	569
Intangible assets, net	$1,173	$1,222

Intangible_Assets_Net_Addition

Intangible Assets, Net - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'
Intangible assets amortization expense	$233	$221	$208

Intangible_Assets_Net_Schedule1

Intangible Assets, Net - Schedule of Estimated Amortization Expense (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'	'
2015	$234	'
2016	222	'
2017	219	'
2018	210	'
2019	169	'
Thereafter	511	'
Intangible assets, net	$1,565	$1,630

Sharebased_Compensation_Plans_1

Share-based Compensation Plans - Additional Information (Detail) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

Nov. 05, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Stockholder Owning in Excess of 10% [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

2011 Stock Incentive Plan [Member]

2011 Stock Incentive Plan [Member]

2013 Equity and Incentive Plan [Member]

2013 Equity and Incentive Plan [Member]

Minimum [Member]

Maximum [Member]

Common Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase in total number of shares available for issue

'

'

'

'

'

'

'

'

'

909,000

'

'

'

Shares granted under stock incentive plan

'

'

'

'

'

'

'

'

'

'

0

'

'

Number of shares available for issuance

'

'

'

'

'

'

'

'

'

'

'

1,151,428

839,465

Percentage of exercise price stock option

100.00%

'

'

110.00%

'

'

'

'

'

'

'

'

'

Option vesting period

'

'

'

'

'

'

'

'3 years

'4 years

'

'

'

'

Option expiration period

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

Intrinsic value of stock option outstanding

'

'

'

'

$17,300,000

'

'

'

'

'

'

'

'

Intrinsic value of stock option exercisable

'

'

'

'

4,000,000

'

'

'

'

'

'

'

'

Common stock value, per share

'

'

'

'

$23.10

'

'

'

'

'

'

'

'

Fair value of stock option vested during period

'

'

'

'

280,000

43,000

37,000

'

'

'

'

'

'

Unrecognized compensation expenses

'

'

'

'

3,400,000

'

'

'

'

'

'

'

'

Weighted average period of expenses to be recognized

'

'

'

'

'3 years 2 months 12 days

'

'

'

'

'

'

'

'

Share-based compensation

$825,000

$25,000

$24,000

'

$825,000

$25,000

$24,000

'

'

'

'

'

'

Sharebased_Compensation_Plans_2

Share-based Compensation Plans - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'
Beginning Balance, Shares	380	133	133
Granted, Shares	715	247	5
Exercised, Shares	-61	'	'
Terminated, Shares	-10	'	-5
Ending Balance, Shares	1,024	380	133
Exercisable, end of year, Shares	200	153	116
Weighted average fair value of options granted during the year, Shares	$6.18	$0.21	$1.75
Beginning Balance, Weighted Average Exercise Price	$1.45	$3.50	$3.78
Granted, Weighted Average Exercise Price	$8.45	$0.35	$3.50
Exercised, Weighted Average Exercise Price	$3.24	'	'
Terminated, Weighted Average Exercise Price	$3.50	'	$11.64
Ending Balance, Weighted Average Exercise Price	$6.21	$1.45	$3.50

Sharebased_Compensation_Plans_3

Share-based Compensation Plans - Summary of Stock Options Outstanding and Exercisable (Detail) (USD $)

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Jun. 30, 2011

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

In Thousands, except Per Share data, unless otherwise specified

Exercise Price 0.35 [Member]

Exercise Price 0.35 [Member]

Exercise Price 3.50 [Member]

Exercise Price 3.50 [Member]

Exercise Price 4.90 [Member]

Exercise Price 4.90 [Member]

Exercise Price 12.00 [Member]

Exercise Price 12.00 [Member]

Exercise Price 14.08 [Member]

Exercise Price 14.08 [Member]

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options outstanding, Exercise Price

$6.21

$1.45

$3.50

$3.78

$0.35

'

$3.50

'

$4.90

'

$12

'

$14.08

'

Stock options outstanding, Number of Options

1,024

380

133

133

242

247

67

133

403

'

157

'

155

'

Stock options Outstanding, Weighted Average Contractual Life Remaining

'

'

'

'

'8 years 6 months 11 days

'9 years 6 months 11 days

'4 years 8 months 27 days

'4 years 5 months 27 days

'9 years 2 months 23 days

'

'9 years 8 months 27 days

'

'9 years 9 months 18 days

'

Stock options exercisable, Exercise Price

'

'

'

'

$0.35

'

$3.50

'

$4.90

'

$12

'

$14.08

'

Stock options exercisable, Number of Options

200

153

116

'

83

71

64

82

47

'

'

'

6

'

Sharebased_Compensation_Plans_4

Share-based Compensation Plans - Summary of Allocation of Share Based Compensation (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Total stock-based compensation expense	$825	$25	$24
Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Total stock-based compensation expense	825	25	24
Stock Options [Member] | Research and development-related [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Total stock-based compensation expense	77	11	9
Stock Options [Member] | General and administrative [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Total stock-based compensation expense	$748	$14	$15

Sharebased_Compensation_Plans_5

Share-based Compensation Plans - Stock Option Pricing Model Assumption (Detail)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Dividend yield	0.00%	0.00%	0.00%
Expected term	'	'	'6 years 3 months
Risk-free interest rate	'	'	1.39%
Risk-free interest rate, minimum	2.04%	1.37%	'
Risk-free interest rate, maximum	2.31%	1.40%	'
Expected volatility	85.00%	63.23%	65.02%
Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Expected term	'6 years	'6 years 3 months	'
Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'
Expected term	'10 years	'10 years	'

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments and Investments - Schedule of Major Category of Company's Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Liabilities:	'	'
Liabilities	'	$2,206
Short-term investments [Member]	'	'
Assets:	'	'
Assets	64,450	14,000
Series B purchase rights [Member]	'	'
Liabilities:	'	'
Liabilities	'	2,096
Warrant liabilities [Member]	'	'
Liabilities:	'	'
Liabilities	'	110
Quoted prices in active markets (Level 1) [Member]	'	'
Liabilities:	'	'
Liabilities	'	'
Quoted prices in active markets (Level 1) [Member] | Short-term investments [Member]	'	'
Assets:	'	'
Assets	'	'
Quoted prices in active markets (Level 1) [Member] | Series B purchase rights [Member]	'	'
Liabilities:	'	'
Liabilities	'	'
Quoted prices in active markets (Level 1) [Member] | Warrant liabilities [Member]	'	'
Liabilities:	'	'
Liabilities	'	'
Significant other observable inputs (Level 2) [Member]	'	'
Liabilities:	'	'
Liabilities	'	'
Significant other observable inputs (Level 2) [Member] | Short-term investments [Member]	'	'
Assets:	'	'
Assets	64,450	14,000
Significant other observable inputs (Level 2) [Member] | Series B purchase rights [Member]	'	'
Liabilities:	'	'
Liabilities	'	'
Significant other observable inputs (Level 2) [Member] | Warrant liabilities [Member]	'	'
Liabilities:	'	'
Liabilities	'	'
Significant unobservable inputs (Level 3) [Member]	'	'
Liabilities:	'	'
Liabilities	'	2,206
Significant unobservable inputs (Level 3) [Member] | Short-term investments [Member]	'	'
Assets:	'	'
Assets	'	'
Significant unobservable inputs (Level 3) [Member] | Series B purchase rights [Member]	'	'
Liabilities:	'	'
Liabilities	'	2,096
Significant unobservable inputs (Level 3) [Member] | Warrant liabilities [Member]	'	'
Liabilities:	'	'
Liabilities	'	$110

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments and Investments - Schedule of Significant Assumptions Used for Valuation (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Warrant liabilities [Member]	'	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'
Fair value of preferred shares	'	$0.15	$0.13
Expected volatility	'	63.23%	65.02%
Warrant liabilities [Member] | Minimum [Member]	'	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'
Exercise price	$0.13	$0.13	$0.13
Expected life (in years)	'1 month 13 days	'3 months 4 days	'1 year 3 months 4 days
Fair value of preferred shares	$0.23	'	'
Risk-free interest rate	0.01%	0.07%	0.27%
Expected volatility	70.00%	'	'
Warrant liabilities [Member] | Maximum [Member]	'	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'
Exercise price	$0.97	$0.97	$0.97
Expected life (in years)	'5 years 8 months 1 day	'7 years	'7 years 2 months 1 day
Fair value of preferred shares	$0.90	'	'
Risk-free interest rate	1.75%	1.69%	1.39%
Expected volatility	85.00%	'	'
Series B purchase rights [Member] | Minimum [Member]	'	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'
Exercise price	$0.15	$0.15	'
Expected life (in years)	'0 years	'29 days	'
Risk-free interest rate	0.06%	0.04%	'
Expected volatility	55.00%	55.00%	'
Series B purchase rights [Member] | Maximum [Member]	'	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'
Exercise price	$0.18	$0.18	'
Expected life (in years)	'1 year	'1 year 10 months 13 days	'
Risk-free interest rate	0.10%	0.25%	'
Expected volatility	85.00%	60.00%	'

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments and Investments - Additional Information (Detail) (USD $)

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Nov. 05, 2013

Nov. 30, 2013

Nov. 05, 2013

Jun. 30, 2013

Nov. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Nov. 30, 2012

Jun. 30, 2013

Nov. 30, 2012

Jun. 30, 2013

Nov. 30, 2012

Apr. 30, 2013

Jun. 30, 2014

Series B purchase rights [Member]

Series B purchase rights [Member]

Series B purchase rights [Member]

Series B-3 convertible preferred stock [Member]

Series B-3 convertible preferred stock [Member]

Series B-3 convertible preferred stock [Member]

Series B-3 convertible preferred stock [Member]

Series B-3 convertible preferred stock [Member]

Series B-3 convertible preferred stock [Member]

Series B-3 convertible preferred stock [Member]

Series B-3 convertible preferred stock [Member]

Series B Convertible Preferred Stock [Member]

Series B-1 convertible preferred stock [Member]

Series B-1 convertible preferred stock [Member]

Series B-2 convertible preferred stock [Member]

Series B-2 convertible preferred stock [Member]

Series B-2 convertible preferred stock [Member]

Series B-2 convertible preferred stock [Member]

Series B purchase rights [Member]

Series B purchase rights [Member]

Series B amendment [Member]

Series B purchase rights [Member]

Series B purchase rights [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

5,000,000

332,091,000

'

'

'

'

'

'

82,670,000

'

'

'

'

290,781,972

67,570,000

'

140,542,000

'

'

'

Preferred stock, shares issued and sold

'

222,842,000

'

'

'

'

58,816,897

58,816,897

'

'

'

'

'

'

66,147,000

66,147,709

122,750,000

'

122,749,639

'

Preferred stock, shares issued and sold, price per share

'

'

'

'

'

'

$0.18

$0.18

'

'

'

'

'

'

'

$0.13

'

'

$0.15

'

Additional shares receivable by Series B holders

'

'

'

'

'

'

'

'

'

82,670,167

'

'

13,387,000

'

'

'

'

140,542,178

'

'

Aggregate purchase price

'

'

'

'

'

'

'

'

'

10,700,000

'

'

'

'

'

'

'

18,200,000

'

'

Fair value of purchase rights issued

'

'

$1,700,000

'

'

'

'

'

'

'

$1,100,000

'

'

'

'

'

'

'

'

$600,000

Proceeds for issuance of share

'

'

'

'

'

10,700,000

'

'

'

'

'

'

'

'

'

'

'

'

18,200,000

'

Change in fair value

'

'

2,904,000

1,207,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase rights converted to convertible preferred stock

'

'

'

800,000

'

'

'

'

'

'

5,000,000

834,000

'

'

'

'

'

'

'

'

Preferred stock, converted to common stock basis

'

'

'

'

'

'

'

$6.38

'

'

'

'

'

'

'

'

'

'

'

'

Fair value allocated to purchase rights

'

'

$5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair_Value_of_Financial_Instru5

Fair Value of Financial Instruments and Investments - Summary of Changes in Fair Value of Company's Level 3 Valuation for Warrant Liabilities and Series B Purchase Rights (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Warrant liabilities [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Beginning balance	$110	$80	$205
Fair value of warrants issued	'	22	79
Fair value of purchase rights issued	'	'	'
Change in fair value during the period	441	8	-204
Preferred Stock Warrants converted to Warrants for Common Stock	-551	'	'
Ending balance	'	110	80
Warrant liabilities [Member] | Series B-3 convertible preferred stock [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Purchase rights converted to convertible preferred stock	'	'	'
Series B purchase rights [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Beginning balance	2,096	'	'
Fair value of warrants issued	'	'	'
Fair value of purchase rights issued	'	1,723	'
Change in fair value during the period	2,904	1,207	'
Preferred Stock Warrants converted to Warrants for Common Stock	'	'	'
Purchase rights converted to convertible preferred stock	'	-800	'
Ending balance	'	2,096	'
Series B purchase rights [Member] | Series B-3 convertible preferred stock [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Purchase rights converted to convertible preferred stock	($5,000)	($834)	'

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Loss Contingencies [Line Items]	'	'	'
Rent expenses under operating leases	$123	$102	$82
Licenses [Member]	'	'	'
Loss Contingencies [Line Items]	'	'	'
Number of license agreements	9	'	'
Number of entities under the license agreement	6	'	'
Royalty and license maintenance paid	$87	$61	$41
Licenses [Member] | Minimum [Member]	'	'	'
Loss Contingencies [Line Items]	'	'	'
Royalty percentage on net sales	0.50%	'	'
Licenses [Member] | Maximum [Member]	'	'	'
Loss Contingencies [Line Items]	'	'	'
Royalty percentage on net sales	4.00%	'	'
Licenses [Member] | University of Florida Research Foundation Licenses [Member]	'	'	'
Loss Contingencies [Line Items]	'	'	'
Number of entities under the license agreement	5	'	'
Licenses [Member] | Company [Member]	'	'	'
Loss Contingencies [Line Items]	'	'	'
Number of entities under the license agreement	1	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Minimum Future Lease Payments Under Non-Cancelable Operating Leases (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
2015	$72
Total minimum future lease payments	$72

Commitments_and_Contingencies_3

Commitments and Contingencies - Minimum Annual Royalty and License Maintenance Payments (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Commitments And Contingencies Disclosure [Abstract]	'
2015	$89
2016	151
2017	152
2018 and every fiscal year thereafter	$156

Concentrations_Additional_Info

Concentrations - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2014
Risks And Uncertainties [Abstract]	'
Percentage of insurance coverage with FDIC	100.00%

Income_Taxes_Significant_Compo

Income Taxes - Significant Components of Deferred Tax Assets and (Liabilities) (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Deferred tax assets:	'	'
Net operating loss carryforwards	$22,661	$18,041
Research and development credit carryforwards	1,262	888
Accruals and other	238	111
Gross deferred tax assets	24,161	19,040
Deferred tax asset valuation allowance	-24,086	-18,956
Total deferred tax assets, net of valuation allowance	75	84
Deferred tax liabilities:	'	'
Depreciation and amortization	-75	-84
Total deferred tax liabilities	-75	-84
Net deferred tax asset (liability)	'	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Taxes [Line Items]	'	'	'
Net operating losses carryforwards	$58,700,000	'	'
Increase in valuation allowance	5,100,000	'	'
Accrued interest and penalties	0	0	0
Minimum [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Net operating losses carryforwards expiration year	'2022	'	'
Maximum [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Net operating losses carryforwards expiration year	'2034	'	'
Research and Development Tax Credit [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Research and development tax credits carry forwards	$1,300,000	'	'
Research and Development Tax Credit [Member] | Minimum [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Research and development tax credits carry forwards	'2027	'	'
Research and Development Tax Credit [Member] | Maximum [Member]	'	'	'
Income Taxes [Line Items]	'	'	'
Research and development tax credits carry forwards	'2043	'	'

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Income Tax Expense (Detail)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Income Tax Disclosure [Abstract]	'	'	'
Federal income tax benefit at statutory rate	-34.00%	-34.00%	-34.00%
State income tax, net of federal benefit	-4.00%	-4.00%	-4.00%
Permanent differences	9.00%	11.00%	-3.00%
Research and development credit	-2.00%	-3.00%	-7.00%
Other	1.00%	2.00%	3.00%
Change in valuation allowance	30.00%	28.00%	45.00%
Effective income tax rate	0.00%	0.00%	0.00%

Convertible_Preferred_Stock_an2

Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

Mar. 04, 2014

Jun. 30, 2014

Apr. 01, 2014

Mar. 31, 2014

Jun. 30, 2013

Nov. 30, 2012

Jun. 30, 2012

Jun. 30, 2014

Nov. 30, 2013

Nov. 05, 2013

Jun. 30, 2013

Apr. 01, 2014

Jun. 30, 2014

Apr. 01, 2014

Apr. 01, 2014

Apr. 01, 2014

Apr. 01, 2014

Common Stock [Member]

Series B-3 convertible preferred stock [Member]

Series B-3 convertible preferred stock [Member]

Series B-3 convertible preferred stock [Member]

IPO [Member]

IPO [Member]

IPO [Member]

IPO [Member]

Over Allotment Option [Member]

Over Allotment Option [Member]

Common Stock [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

'

14,082,000

'

'

109,000

'

'

4,853,000

'

'

'

'

'

4,166,667

'

'

625,000

Common stock, share price

'

'

'

'

'

'

'

'

$0.18

$0.18

'

'

'

$12

'

'

$12

Proceeds from initial public offering

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$51,600,000

'

Convertible preferred stock, shares issued upon conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,120,081

'

'

Warrants exercisable for common stock, converted from warrants exercisable for preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

49,811

'

'

Reclassification of convertible preferred stock warrant liability to additional paid-in capital

'

$551,000

'

'

'

'

'

'

'

'

'

$551,000

'

'

'

'

'

Preferred stock, shares issued and sold

'

'

'

'

222,842,000

'

'

'

58,816,897

58,816,897

'

'

0

'

'

'

'

Convertible preferred stock, shares outstanding

'

0

'

'

222,842,000

'

'

'

'

'

'

'

0

'

'

'

'

Convertible preferred stock, par value

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible preferred stock authorized to be issued

'

5,000,000

'

'

332,091,000

'

'

'

'

'

82,670,000

'

'

'

'

'

'

Common stock, shares authorized

'

150,000,000

150,000,000

'

410,000,000

410,000,000

45,102,000

'

'

'

'

'

'

'

'

'

'

Common stock, par value

'

$0.00

$0.00

$0.00

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split ratio

0.02857

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split ratio description

'

'On March 4, 2014, the Company effected a 1-for-35 reverse stock split of its common stock, whereby each share of common stock, $0.001 par value, outstanding immediately prior to that date was combined, reclassified and changed into one thirty-fifth (1/35) of a fully paid and non-assessable share of common stock.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible_Preferred_Stock_an3

Convertible Preferred Stock and Stockholders' Equity (Deficit) - Schedule of Convertible Preferred Stock (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Nov. 30, 2012	Jun. 30, 2013	Nov. 30, 2013	Nov. 05, 2013	Jun. 30, 2013
In Thousands, except Share data, unless otherwise specified			Series A-1 convertible preferred stock [Member]	Series A-1A convertible preferred stock [Member]	Series B-1 convertible preferred stock [Member]	Series B-1 convertible preferred stock [Member]	Series B-2 convertible preferred stock [Member]	Series B-3 convertible preferred stock [Member]	Series B-3 convertible preferred stock [Member]	Series B-3 convertible preferred stock [Member]
Temporary Equity [Line Items]	'	'	'	'	'	'	'	'	'	'
Shares Authorized	5,000,000	332,091,000	29,737,000	11,572,000	67,570,000	'	140,542,000	'	'	82,670,000
Shares Issued	'	222,842,000	22,466,000	11,479,000	66,147,000	66,147,709	122,750,000	58,816,897	58,816,897	'
Carrying Value	'	$58,103	$21,526	$10,998	$6,539	'	$19,040	'	'	'
Shares Outstanding	0	222,842,000	22,466,000	11,479,000	66,147,000	'	122,750,000	'	'	'

Convertible_Preferred_Stock_an4

Convertible Preferred Stock and Stockholders' Equity (Deficit) - Shares of Common Stock Reserved for Future Issuance (Detail)	Jun. 30, 2014
In Thousands, unless otherwise specified
Class of Stock [Line Items]	'
Common stock reserved for future issuance	1,913
Common Stock Warrants [Member]	'
Class of Stock [Line Items]	'
Common stock reserved for future issuance	50
Stock Options Issued and Outstanding [Member]	'
Class of Stock [Line Items]	'
Common stock reserved for future issuance	1,024
Equity and Incentive Plan 2013 [Member]	'
Class of Stock [Line Items]	'
Common stock reserved for future issuance	839

Accrued_Expenses_Schedule_of_A

Accrued Expenses - Schedule of Accrued Expenses (Detail) (USD $)	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified
Schedule Of Accrued Liabilities [Line Items]	'	'
Accrued expenses	$1,585	$360
Research and development-related [Member]	'	'
Schedule Of Accrued Liabilities [Line Items]	'	'
Accrued expenses	1,008	61
Compensation-related [Member]	'	'
Schedule Of Accrued Liabilities [Line Items]	'	'
Accrued expenses	575	298
Other [Member]	'	'
Schedule Of Accrued Liabilities [Line Items]	'	'
Accrued expenses	$2	$1

Defined_Contribution_Plan_Addi

Defined Contribution Plan - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'
Percentage of deferred compensation	25.00%	'	'
Total matching contributions to the plan	$60	$40	$34
Maximum [Member]	'	'	'
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]	'	'	'
Percentage of deferred compensation match by employer	4.00%	'	'

Quarterly_Financial_Informatio2

Quarterly Financial Information - Summary of Quarterly Information (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenue	$124	$232	$515	$258	$377	$116	$190	$259	$1,129	$942	$1,082
Loss from operations	-4,425	-3,260	-2,905	-1,966	-1,287	-951	-796	-560	-12,556	-3,594	-2,059
Net loss	($4,521)	($3,588)	($735)	($7,064)	($1,428)	($1,622)	($1,336)	($604)	($15,908)	($4,990)	($1,924)
Net loss per common share, basic and diluted	($0.32)	($25.45)	($6.74)	($64.81)	($13.10)	($14.88)	($12.26)	($5.54)	($4.46)	($45.78)	($17.65)

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	12 Months Ended				0 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Apr. 01, 2014	Apr. 01, 2014	Aug. 01, 2014	Jul. 30, 2014	Aug. 01, 2014
			IPO [Member]	Over Allotment Option [Member]	Subsequent event [Member]	Subsequent event [Member]	Subsequent event [Member]
						IPO [Member]	Over Allotment Option [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'	'
Common stock, shares issued	14,082,000	109,000	4,166,667	625,000	'	2,000,000	300,000
Common stock, share price	'	'	$12	$12	'	$15	$15
Aggregate net proceeds received	$51,607	'	'	'	$32,000	'	'

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts (Detail) (Deferred Tax Valuation Allowance [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Deferred Tax Valuation Allowance [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Beginning of Period	$18,956	$17,468	$16,487
Additions, Charge (Benefit) to Expenses	5,130	1,488	981
Additions, To (from) Other Accounts	'	'	'
Deductions	'	'	'
End of Period	$24,086	$18,956	$17,468